Product Information
FENOFIBRATE 130 MG CAPSULE is a generic product labeled by Apotex Corp., priced at $0.7022 per EA under NDC 60505312109. Its NADAC has been published 542 times since May 18, 2016.
FDA first approved this application on Jul 26, 2013. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
130 mg/1
Manufacturer
Apotex Corp.NDC
60505312109
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
FENOFIBRATEApproval Type
Generic (ANDA)
FDA Application
ANDA202252FDA Approved
7/26/2013
TE Code
AB
On Market Since
7/26/2013
Pharmacological Classes
Price Statistics
The NADAC for FENOFIBRATE 130 MG CAPSULE has been published 542 times since May 18, 2016, and over the history we have for it it has declined 82.2%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.7022 per EA |
|---|---|
| All-time high | $4.0556 (Jul 13, 2016) |
| All-time low | $0.5104 (Sep 20, 2023) |
| 52-week high | $0.8173 |
| 52-week low | $0.6427 |
| Median price | $1.6340 |
| Average price | $1.6303 |
| Largest weekly change | -52.7% (Aug 23, 2023) |
| Weeks tracked | 542 |
| Tracking since | May 18, 2016 |
Generic Alternatives
The matcher finds 3 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 3% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Apotex Corp. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Fenofibrate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Peroxisome Proliferator Receptor alpha Agonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of FENOFIBRATE 130 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for FENOFIBRATE 130 MG CAPSULE, manufactured by Apotex Corp., is $0.7022 per EA (NDC 60505312109), effective Sep 30, 2026.
How has the price of FENOFIBRATE 130 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for FENOFIBRATE 130 MG CAPSULE has declined 82.2%. It has been tracked across 542 weekly CMS publications since May 18, 2016.
What are the highest and lowest recorded NADAC prices for FENOFIBRATE 130 MG CAPSULE?
Since May 18, 2016, the NADAC for FENOFIBRATE 130 MG CAPSULE has ranged from a low of $0.5104 (Sep 20, 2023) to a high of $4.0556 (Jul 13, 2016), with a median of $1.6340 per EA.
Are there cheaper alternatives to FENOFIBRATE 130 MG CAPSULE?
Yes. 3 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, FENOFIBRATE 130 MG CAPSULE, is $0.6795 per EA — about 3% below FENOFIBRATE 130 MG CAPSULE.
Who manufactures FENOFIBRATE 130 MG CAPSULE?
FENOFIBRATE 130 MG CAPSULE (NDC 60505312109) is labeled by Apotex Corp., and CMS classifies it as a generic product.